1. Home
  2. WOOF vs SRPT Comparison

WOOF vs SRPT Comparison

Compare WOOF & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WOOF
  • SRPT
  • Stock Information
  • Founded
  • WOOF 1965
  • SRPT 1980
  • Country
  • WOOF United States
  • SRPT United States
  • Employees
  • WOOF N/A
  • SRPT N/A
  • Industry
  • WOOF Other Specialty Stores
  • SRPT Biotechnology: Pharmaceutical Preparations
  • Sector
  • WOOF Consumer Discretionary
  • SRPT Health Care
  • Exchange
  • WOOF Nasdaq
  • SRPT Nasdaq
  • Market Cap
  • WOOF N/A
  • SRPT N/A
  • IPO Year
  • WOOF 2021
  • SRPT 1997
  • Fundamental
  • Price
  • WOOF $2.63
  • SRPT $20.28
  • Analyst Decision
  • WOOF Buy
  • SRPT Buy
  • Analyst Count
  • WOOF 8
  • SRPT 26
  • Target Price
  • WOOF $3.75
  • SRPT $70.92
  • AVG Volume (30 Days)
  • WOOF 5.9M
  • SRPT 6.5M
  • Earning Date
  • WOOF 06-05-2025
  • SRPT 08-06-2025
  • Dividend Yield
  • WOOF N/A
  • SRPT N/A
  • EPS Growth
  • WOOF N/A
  • SRPT N/A
  • EPS
  • WOOF N/A
  • SRPT N/A
  • Revenue
  • WOOF $6,080,721,000.00
  • SRPT $2,233,371,000.00
  • Revenue This Year
  • WOOF $0.04
  • SRPT $26.87
  • Revenue Next Year
  • WOOF $1.41
  • SRPT $3.15
  • P/E Ratio
  • WOOF N/A
  • SRPT N/A
  • Revenue Growth
  • WOOF N/A
  • SRPT 59.15
  • 52 Week Low
  • WOOF $2.23
  • SRPT $18.30
  • 52 Week High
  • WOOF $6.29
  • SRPT $173.25
  • Technical
  • Relative Strength Index (RSI)
  • WOOF 39.14
  • SRPT 20.82
  • Support Level
  • WOOF $2.38
  • SRPT $18.30
  • Resistance Level
  • WOOF $2.77
  • SRPT $22.98
  • Average True Range (ATR)
  • WOOF 0.20
  • SRPT 2.20
  • MACD
  • WOOF -0.08
  • SRPT -1.46
  • Stochastic Oscillator
  • WOOF 18.12
  • SRPT 8.90

About SRPT Sarepta Therapeutics Inc. (DE)

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.

Share on Social Networks: